3D Printing And The First Amendment: What A Gun Rights Case Could Mean For US FDA
A landmark legal case over 3D-printed guns doesn’t involve FDA – but it is worth considering how the issues are likely to apply to the drug approval process in years to come. The right to bear arms may rely on the Second Amendment, but the key for FDA is how courts look at the First Amendment in the context of new technology.
You may also be interested in...
Alzheimer drug’s development was discontinued after third disappointing Phase III trial, but given the kind of FDA commissioner candidates getting meetings with the President, maybe Lilly should reconsider.
FDA's Emerging Technology Team is guiding a diverse array of new manufacturing technologies through the agency's regulatory review process that could add market niches and possibly even fundamentally restructure the pharmaceutical industry.
A US FDA Advisory Committee’s overwhelming rejection of FibroGen/AstraZeneca’s oral anti-anemia agent is a big setback for the sponsor. But the committee’s reaction to novel strategies used to try to save the application has an important message for all drug developers about the limits of those approaches.